SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis
Life Science Alliance · 2023
DOI: 10.26508/lsa.202201457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2023. Verfasst von Akihiro Ikenaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, MicroRNAs, Muscular Atrophy, Spinal, Survival of Motor Neuron 1 Protein. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, MEXT | Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a congenital neuromuscular disease caused by the mutation or deletion of the survival motor neuron 1 (SMN1) gene. Although the primary cause of progressive muscle atrophy in SMA has classically been considered the degeneration of motor neurons, recent studies have indicated a skeletal muscle–specific pathological phenotype such as impaired mitochondrial function and enhanced cell death. Here, we found that the down-regulation of SMN causes mitochondrial dysfunction and subsequent cell death in in vitro models of skeletal myogenesis with both a murine C2C12 cell line and human induced pluripotent stem cells. During myogenesis, SMN binds to the upstream genomic regions of MYOD1 and microRNA (miR)-1 and miR-206. Accordingly, the loss of SMN down-regulates these miRs, whereas supplementation of the miRs recovers the mitochondrial function, cell survival, and myotube formation of SMN-deficient C2C12, indicating the SMN-miR axis is essential for myogenic metabolic maturation. In addition, the introduction of the miRs into ex vivo muscle stem cells derived from Δ7-SMA mice caused myotube formation and muscle contraction. In conclusion, our data revealed novel transcriptional roles of SMN during myogenesis, providing an alternative muscle-oriented therapeutic strategy for SMA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
- Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Drug Discovery Technology Development Office, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
- Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan msaito@cira.kyoto-u.ac.jp.
ORCID-Profile: Akira Niwa, Megumu K Saito
Förderung
- Japan Society for the Promotion of Science
- MEXT | Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- iPS Cell Research Fund
Zitieren
APA
Ikenaka, A., Kitagawa, Y., Yoshida, M., Lin, C. Y., Niwa, A., Nakahata, T., & Saito, M. K. (2023). SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis. Life Science Alliance. https://doi.org/10.26508/lsa.202201457
Vancouver
Ikenaka A, Kitagawa Y, Yoshida M, Lin CY, Niwa A, Nakahata T, et al. SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis. Life Science Alliance. 2023. doi:10.26508/lsa.202201457
BibTeX
@article{Ikenaka2023,
author = {Ikenaka, Akihiro and Kitagawa, Yohko and Yoshida, Michiko and Lin, Chuang-Yu and Niwa, Akira and Nakahata, Tatsutoshi and Saito, Megumu K},
title = {SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis},
journal = {Life Science Alliance},
year = {2023},
doi = {10.26508/lsa.202201457}
}
EUVIMED